Three U.S. senators ask Mylan for EpiPen military reimbursements
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
(Reuters) - Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense.
The reimbursement demand came in a letter on Monday to Mylan Chief Executive Heather Bresch, from Senate Judiciary Chairman Charles Grassley, an Iowa Republican, and committee members Richard Blumenthal of Connecticut and Amy Klobuchar of Minnesota, both Democrats.
"We are alarmed that Mylan may have overcharged our military for this life-saving drug," the Senators wrote. They said Mylan for years may have knowingly misclassified EpiPen as a generic product in order to avoid higher rebates the company would have had to pay state and federal Medicaid programs had it been classified as a branded product.
The Medicaid rebate for a generic is 13 percent compared with a minimum of 23.1 percent for a branded medicine.
Mylan spokeswoman Nina Devlin declined to comment on the letter, or its demands.
The drug company has come under fire from consumers and politicians in recent months for raising the U.S. list price on a pack of two EpiPen injectors nearly six-fold to $600 since 2008. Lawmakers, including Grassley, have called for investigations into Mylan's pricing, helping put the product in the spotlight amid a larger debate over big drug price increases in the United States.
Pentagon spending on EpiPen jumped to $57 million over the past year from $9 million in 2008, an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies, Reuters reported on Oct. 28, citing previously unreported data.
The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order. But nearly half of its spending was at retail pharmacies where it most recently paid an average of $509 for EpiPen and $528 for EpiPen Jr two-packs - three times higher than its discounted rate, according to the data.
The Senate Judiciary Committee is slated to hold a hearing Nov. 30 on EpiPen pricing and related matters.
(Reporting by Ransdell Pierson; Editing by Bill Rigby)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vanda Pharma (VNDA) Enters Settlement with Apotex; Fanapt Licensing Agreement Entered
- AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review
- Prudential investigating Wells Fargo partnership after scandal
Create E-mail Alert Related CategoriesFDA, Litigation, Reuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!